The NeurologyLive® MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.
March 16th 2024
A recent analysis of a phase 2 trial showed that repeated intrathecal injections of MSC therapy led to significant reductions in serum biomarkers and improvements in neurological function for progressive MS.
Analyzing Phase 2 CALLIPER Trial of IMU-838 for Progressive MS: Robert J. Fox, MD
March 3rd 2024The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from an interim analysis of the phase 2 CALLIPER trial assessing vidofludimus calcium in progressive multiple sclerosis. [WATCH TIME: 4 minutes]
Ozanimod's Consistent Efficacy in Long-Term Treatment for Multiple Sclerosis: Jeffery Cohen, MD
March 1st 2024The director of Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research talked about recent findings on long-term impact of ozanimod in patients with relapsing-remitting multiple sclerosis presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]
Phase 3 DAYBREAK Trial Highlights Long-Term Efficacy of Ozanimod for Relapsing Multiple Sclerosis
February 29th 2024Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.
The Evolving Landscape of Treatments for Multiple Sclerosis in 2024: Enrique Alvarez, MD, PhD
February 14th 2024The associate professor of neurology at the University of Colorado School of Medicine talked about promising developments in multiple sclerosis treatment strategies for 2024. [WATCH TIME: 6 minutes]
A Medical Preview of 2024 for Multiple Sclerosis and Related Disorders: Jiwon Oh, MD, PhD
February 11th 2024The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital shared thoughts on the promising advancements in the multiple sclerosis field for 2024. [WATCH TIME: 5 minutes]
Multiple Sclerosis Treatment Decision-Making With MS-SUPPORT Tool
February 8th 2024Nananda Col, MD, MPH, MPP, FACP, the president and founder of Shared Decision Making Resources, spoke about usage of the MS-SUPPORT tool in a recent study to foster shared decision-making between patients and clinicians in multiple sclerosis.
Emphasizing Shared Decision Making and Emerging Strategies in MS Treatment: Patricia K. Coyle, MD
February 5th 2024The professor of neurology at Stony Brook University Medical Center discussed the significance of shared decision making in multiple sclerosis care and promising developments in treatment strategies. [WATCH TIME: 3 minutes]
Case Study Reports Positive Impact of Antiviral Therapy Tenofovir in MS, Warranting Further Research
February 3rd 2024In a case report, an HIV-positive patient with active multiple sclerosis showed reduced disease activity with tenofovir-containing antiretrovirals, suggesting potential MS treatment benefits.
Making Improvements to Geographic Spacing, Access to Neurologists and MS Care
February 1st 2024Marisa McGinley, DO, a staff neurologist at Cleveland Clinic’s Mellen Center for MS Treatment and Research, provided forward thoughts on the healthcare reach of neurologists and care access for patients with multiple sclerosis.
Shared Decision-Making Intervention MS-SUPPORT Provides Several Benefits to Patients With MS
January 31st 2024An online shared decision-making tool showed feasibility in most patients with multiple sclerosis, with reported improvements in understanding treatment options and adherence to treatment.